Use of CV secondary prevention drugs leaves a lot to be desired

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.637, 2011-01, pp. : 5-5

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Primary and Secondary Stroke Prevention with Antiplatelet Drugs

Current Pharmaceutical Design, Vol. 12, Iss. 10, 2006-04 ,pp. : 1293-1297

Bentham Science Publishers

Access to resources Recommend Favorite

Atorvastatin: A Pharmacoeconomic Review of its Use in the Primary and Secondary Prevention of Cardiovascular Events

By Plosker Greg L. Lyseng-Williamson Katherine A.

PharmacoEconomics, Vol. 25, Iss. 12, 2007-01 ,pp. : 1031-1053

Adis International

Access to resources Recommend Favorite

Clopidogrel beats aspirin for CV event prevention in Germany

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 545, 2008-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite

Pharmacotherapy for the Secondary Prevention of Stroke

By Toyoda Kazunori

Drugs, Vol. 69, Iss. 6, 2009-01 ,pp. : 633-647

Adis International

Access to resources Recommend Favorite

Clopidogrel for the secondary prevention of stroke

By Diener Hans-Christoph Ringleb Peter A Savi Pierre

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 5, 2005-05 ,pp. : 755-764

Informa Healthcare

Access to resources Recommend Favorite